Paula Cramer

8PUBLICATIONS
35CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 07, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Jennifer A Woyach, Lugui Qiu, Sebastian Grosicki

|Jan 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Moritz Fürstenau, Sandra Robrecht, Christof Schneider

|Nov 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Petra Langerbeins, Sandra Robrecht, Pascal Nieper

|Aug 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

Florian Simon, Rudy Ligtvoet, Sandra Robrecht

|Apr 15, 2024
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.

Petra Langerbeins, Adam Giza, Sandra Robrecht

|Apr 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.

Moritz Fürstenau, Adam Giza, Jonathan Weiss

Pageof 2

Frequent Collaborators

7 joint publications

Petra Langerbeins

6 joint publications

Moritz Fürstenau

5 joint publications

Florian Simon

4 joint publications

Othman Al-Sawaf